Sp1051
TYPE-2 IMMUNITY IN EOSINOPHILIC ESOPHAGITI
Date
May 9, 2023
Explore related products in the following collection:
Society: AGA
This session will feature speakers who will examine the mechanisms of inflammation and epithelial tissue remodeling during eosinophilic esophagitis (EoE). Epithelial cell and immune cell biology will be discussed. Biologics currently used for targeted therapeutic interventions in EoE will be considered.
This session will feature speakers who will examine the mechanisms of inflammation and epithelial tissue remodeling during eosinophilic esophagitis (EoE). Epithelial cell and immune cell biology will be discussed. Biologics currently used for targeted therapeutic interventions in EoE will be considered.
Presenter
Tracks
Related Products
DETERGENT-CONTAINING TOOTHPASTE DECREASES MUCOSAL IMPEDANCE IN THE ESOPHAGUS
Background: Eosinophilic Esophagitis (EoE) is one of the most predominant causes of chronic esophageal symptoms in children. Pathological changes of the esophageal epithelium in EoE are characterized by basal cell hyperplasia (BCH), infiltration of eosinophils and elevated levels of cytokines (e.g…
IL-13-INDUCED STAT3-DEPENDENT REGULATORY NETWORKS DRIVE ESOPHAGEAL EPITHELIAL PROLIFERATION IN EOSINOPHILIC ESOPHAGITIS.
Background: Eosinophilic Esophagitis (EoE) is one of the most predominant causes of chronic esophageal symptoms in children. Pathological changes of the esophageal epithelium in EoE are characterized by basal cell hyperplasia (BCH), infiltration of eosinophils and elevated levels of cytokines (e.g…
PLACEHOLDER
Perturbations in the gut mucosal immune response contributes to IBD. Non-immune cell popopulations including epithelial and stromal cells also play an important role in intestinal inflammation…
ENCAPSULATED MICROBIOTA TRANSPLANT THERAPY IMPROVES PARTIAL MAYO SCORES IN ULCERATIVE COLITIS AND INDUCES RAPID ENGRAFTMENT COMPARED TO PLACEBO CONTROL
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
